R&D News | pharmaphorum

News

Merck's Lagevrio 'no better than placebo' in COVID hospitali...

A UK study has found that Merck & Co's oral COVID-19 therapy Lagevrio was unable to reduce hospitalisations compared to placebo in patients at higher risk from the virus, adding fuel to

News

Cells and biological chain,molecules and abstract conception,3d rendering. Computer digital drawing.

AZ/BenevolentAI collab achieves AI-enabled further milestone...

Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZ

News

Click and bio-orthogonal chemistry take Nobel Prize 2022

The Royal Swedish Academy of Sciences has decided to award this year’s Nobel Prize in Chemistry to Carolyn R.

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

News

As gonorrhoea threat grows, Intravacc gets $14m for vaccine ...

Dutch biotech Intravacc has been given a $14.6 million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise aroun

News

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

Merck's Lagevrio 'no better than placebo' in COVID hospitali...

AZ/BenevolentAI collab achieves AI-enabled further milestone...

Click and bio-orthogonal chemistry take Nobel Prize 2022

Vir awarded $1 billion multi-year BARDA influenza contract

As gonorrhoea threat grows, Intravacc gets $14m for vaccine ...

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

Moderna's Q1 revenues rocket, thanks to ex-US sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks